Altamira Therapeutics (CYTO) News Today $0.30 -0.11 (-25.94%) (As of 12/19/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Altamira Therapeutics Transitions to OTCQB Following Nasdaq DelistingDecember 21 at 10:48 PM | markets.businessinsider.comAltamira Therapeutics Announces Transition from NASDAQ to OTC MarketsDecember 20 at 8:00 AM | globenewswire.comAltamira Therapeutics Provides Update on Nasdaq ListingOctober 4, 2024 | globenewswire.comAltamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal SpraySeptember 27, 2024 | globenewswire.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call TranscriptSeptember 26, 2024 | msn.comAltamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ...September 25, 2024 | finance.yahoo.comAltamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call TranscriptSeptember 24, 2024 | seekingalpha.comAltamira Therapeutics Provides Business Update and First Half 2024 Financial ResultsSeptember 24, 2024 | globenewswire.comNuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East AsiaSeptember 23, 2024 | finance.yahoo.comLondon's SMEs must get the connectivity they deserve to thrive and growSeptember 21, 2024 | msn.comAltamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024September 20, 2024 | globenewswire.comAltamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingSeptember 19, 2024 | globenewswire.comAltamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingSeptember 17, 2024 | globenewswire.comAltamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11September 3, 2024 | globenewswire.comREPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)August 26, 2024 | globenewswire.comAltamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkAugust 23, 2024 | globenewswire.comAltamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesAugust 16, 2024 | globenewswire.comAltamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsAugust 12, 2024 | globenewswire.comAltamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesJuly 19, 2024 | globenewswire.comAltamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementJune 20, 2024 | globenewswire.comAltamira Therapeutics Provides Business UpdateMay 28, 2024 | globenewswire.comWhat's Going On With Altamira Therapeutics Stock?May 23, 2024 | msn.comAltamira stock soars 45% on Bentrio social media postingsMay 23, 2024 | msn.comAltamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalMay 23, 2024 | globenewswire.comAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationMay 1, 2024 | globenewswire.comAltamira reports publication of positive results from NASAR clinical trial with BentrioApril 24, 2024 | msn.comAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalApril 24, 2024 | globenewswire.comDiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)April 15, 2024 | finance.yahoo.comAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | seekingalpha.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | msn.comAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsApril 10, 2024 | finance.yahoo.comAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024April 4, 2024 | globenewswire.comAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 26, 2024 | finanznachrichten.deCrude Oil Moves Higher; US New Home Sales Fall In FebruaryMarch 26, 2024 | markets.businessinsider.comWhy Altamira Therapeutics Stock Is Racing HigherMarch 25, 2024 | msn.comAltamira stock rallies 44% on Univercells mRNA collaborationMarch 25, 2024 | msn.comAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 25, 2024 | globenewswire.comAltamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalFebruary 7, 2024 | finance.yahoo.comAltamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent ApplicationJanuary 24, 2024 | marketwatch.comAltamira Therapeutics stock jumps 7% as it files for second patentJanuary 24, 2024 | msn.comAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentJanuary 24, 2024 | finance.yahoo.comAltamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitJanuary 8, 2024 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementDecember 29, 2023 | finance.yahoo.comTrading was temporarily halted for "CYTO" at 09:12 AM with a stated reason of "LULD pause."December 13, 2023 | marketbeat.comTrading was temporarily halted for "CYTO" at 07:12 PM with a stated reason of "News pending."December 13, 2023 | marketbeat.comAltamira shares sink over 40% on corporate, stock split updatesDecember 11, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Down 50% TodayDecember 11, 2023 | msn.comAltamira Therapeutics Provides Investor and Business UpdateDecember 11, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | finance.yahoo.comAltamira Therapeutics to Host Investor & Business Update Call on December 11thDecember 5, 2023 | finance.yahoo.com Get Altamira Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… CYTO Media Mentions By Week CYTO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTO News Sentiment▼0.990.60▲Average Medical News Sentiment CYTO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTO Articles This Week▼20▲CYTO Articles Average Week Get Altamira Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GTBP News HOTH News CANF News ELAB News IMCC News BMRA News AEZS News PPBT News BNOX News UPXI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altamira Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTO Stock Alerts